3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
57
Neoplasm Metastasis
3
Stage II Prostate Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Prostate Cancer With ≤10 Bone Metastases
1
Prostate Cancer Metastatic Disease
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Patient Preference
1
Neoplasms
1
Neoadjuvant Therapy
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Low Risk Prostate Cancer
1
High-Risk and Oligometastatic Prostate Cancer
1
High Risk Prostate Cancer
1
Hematologic Neoplasms
1
Genital Diseases, Male
1
Castration Levels of Testosterone
1
Carcinoma, Small Cell
1
Bulbo-Spinal Atrophy, X-Linked
1
Advanced Prostate Carcinoma
1
Interventions
radium Ra 223 dichloride
1
niraparib
1
enzalutamide
1
darolutamide
1
capivasertib
1
cabazitaxel
1
apalutamide
1
abiraterone
1
Solutions
1
Prednisone
1
Injections
1
Docetaxel
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Metastatic Castration-resistant Prostate Cancer (mCRPC)
×
apalutamide
×
Clear all
NCT03903835
2025-04-09
ProBio
Karolinska Institutet
Phase 3
Recruiting
750 enrolled